000145462 001__ 145462
000145462 005__ 20241030091919.0
000145462 0247_ $$2doi$$a10.7554/eLife.96343
000145462 0248_ $$2sideral$$a140331
000145462 037__ $$aART-2024-140331
000145462 041__ $$aeng
000145462 100__ $$0(orcid)0000-0003-4058-2888$$aMaity, Ritwik
000145462 245__ $$aMerging multi-omics with proteome integral solubility alteration unveils antibiotic mode of action
000145462 260__ $$c2024
000145462 5060_ $$aAccess copy available to the general public$$fUnrestricted
000145462 5203_ $$aAntimicrobial resistance is responsible for an alarming number of deaths, estimated at 5 million per year. To combat priority pathogens, like Helicobacter pylori, the development of novel therapies is of utmost importance. Understanding the molecular alterations induced by medications is critical for the design of multi-targeting treatments capable of eradicating the infection and mitigating its pathogenicity. However, the application of bulk omics approaches for unraveling drug molecular mechanisms of action is limited by their inability to discriminate between target-specific modifications and off-target effects. This study introduces a multi-omics method to overcome the existing limitation. For the first time, the Proteome Integral Solubility Alteration (PISA) assay is utilized in bacteria in the PISA-Express format to link proteome solubility with different and potentially immediate responses to drug treatment, enabling us the resolution to understand target-specific modifications and off-target effects. This study introduces a comprehensive method for understanding drug mechanisms and optimizing the development of multi-targeting antimicrobial therapies.
000145462 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E45-23R$$9info:eu-repo/grantAgreement/EC/H2020/801586/EU/International Doctoral Programme for Talent Attraction to the Campus of International Excellence of the Ebro Valley/IberusTalent$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 801586-IberusTalent$$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-107293GB-I00$$9info:eu-repo/grantAgreement/ES/MICINN/PID2022-141068NB-I00
000145462 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000145462 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000145462 700__ $$aZhang, Xuepei
000145462 700__ $$aLiberati, Francesca Romana
000145462 700__ $$aScribani Rossi, Chiara
000145462 700__ $$aCutruzzolá, Francesca
000145462 700__ $$aRinaldo, Serena
000145462 700__ $$aGaetani, Massimiliano
000145462 700__ $$0(orcid)0000-0003-2076-844X$$aAínsa, José Antonio$$uUniversidad de Zaragoza
000145462 700__ $$0(orcid)0000-0002-2879-9200$$aSancho, Javier$$uUniversidad de Zaragoza
000145462 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000145462 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000145462 773__ $$g13 (2024), 21 pp.$$peLife (Cambridge)$$teLife$$x2050-084X
000145462 8564_ $$s7248801$$uhttps://zaguan.unizar.es/record/145462/files/texto_completo.pdf$$yVersión publicada
000145462 8564_ $$s2601053$$uhttps://zaguan.unizar.es/record/145462/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000145462 909CO $$ooai:zaguan.unizar.es:145462$$particulos$$pdriver
000145462 951__ $$a2024-10-30-08:48:58
000145462 980__ $$aARTICLE